BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 204 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2019. The put-call ratio across all filers is 0.22 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $4,286,000 | -72.4% | 50,000 | -85.9% | 1.17% | -78.9% |
Q2 2019 | $15,546,000 | +18.0% | 355,000 | +38.7% | 5.53% | -11.8% |
Q1 2019 | $13,177,000 | +47.7% | 256,000 | +6.1% | 6.27% | -7.9% |
Q4 2018 | $8,924,000 | +27.6% | 241,300 | +29.5% | 6.81% | +172.7% |
Q3 2018 | $6,995,000 | -17.2% | 186,300 | -12.9% | 2.50% | +66.0% |
Q2 2018 | $8,449,000 | – | 213,800 | – | 1.50% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |